Information Provided By:
Fly News Breaks for January 15, 2016
NVS
Jan 15, 2016 | 05:37 EDT
Barclays analyst Michael Leuchten downgraded Novartis to Underweight with a price target of CHF 85. The majority of the company's top pine growth is dependent on two produces, Entresto and Cosentyx, and expectations may be tough to meet, Leuchten tells investors in a research note.